Citations

Showing 10 of 108081 citations.

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. Gabriela , Chiaro, Marco Del , Tempero, Margaret A. , Malafa, Mokenge P. , Benson, Al B. , Cardin, Dana B. , Christensen, Jared A. , Czito, Brian G. , Dillhoff, Mary , Donahue, Timothy R. , Hardacre, Jeffrey M., Klute, Kelsey , Ko, Andrew H. , LoConte, Noelle K. , Lowy, Andrew M. , Masood, Ashiq , Moravek, Cassadie, Nakakura, Eric K. , Narang, Amol , Nardo, Lorenzo , Obando, Jorge, Reddy, Sushanth , Reyngold, Marsha , Scaife, Courtney L. , Shen, Jeanne , Truty, Mark J. , Vollmer, Charles M., Wolff, Robert A. , Wolpin, Brian M. , McCullough, Beth, Lubin, Senem, Darlow, Susan, Cardin, Dana B , LoConte, Noelle , Chung, Vincent , Dotan, Efrat , Fountzilas, Christos , Glazer, Evan S. , Hawkins, William G , Kunstman, John W. , Polanco, Patricio Marcelo

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 11, 2023 | Volume: 21 | Issue: 7 | Pages: 753-782

10.6004/jnccn.2023.0034 | PMID 37433437 Get It

Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Benson, Al B. , D’Angelica, Michael I. , Abbott, Daniel E. , Ahmed, Aijaz, Anaya, Daniel A. , Are, Chandrakanth , Binder, David C. , Bowlus, Christopher L. , Burgoyne, Adam M. , Castellanos, Jason , Chahal, Prabhleen , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Jennings, Lawrence J. , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Reddy, Sanjay S. , Sahai, Vaibhav , Singh, Gagandeep , Stein, Stacey , Yopp, Adam C. , McMillian, Nicole R., Schonfeld, Ryan, Hochstetler, Cindy, Bowlus, Christopher L , Sahai, Vaibhav , Abrams, Thomas A. , Anders, Robert A. , Bachini, Melinda , Borad, Mitesh J. , Brown, Daniel B. , Glazer, Evan S. , Hawkins, William G , Levine, Matthew H , Raman, Steven S. , Ronnekleiv-Kelly, Sean M , Turk, Anita , Vauthey, Jean‐Nicolas , Venook, Alan P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 11, 2023 | Volume: 21 | Issue: 7 | Pages: 694-704

10.6004/jnccn.2023.0035 | PMID 37433432 Get It

In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.
Recipient and kidney graft outcomes of deceased donors with human immunodeficiency virus in the United States
Fontana, Lauren , El‐Rifai, Rasha , Bregman, Adam , Spong, Richard , Kirchner, Varvara A. , Kirchner, Varvara , Swanson, Kurtis J. , Pruett, Timothy L. , Jackson, Scott , Riad, Samy

Mayo Clinic

Transplant Infectious Disease | July 11, 2023 | Volume: 25 | Issue: 4 | Pages: No page available

10.1111/tid.14093 | PMID 37432941 Get It

AbstractBackgroundThe HIV Organ Policy Equity (HOPE) act afforded transplantation of organs from donors who have HIV. Herein we compared the long‐term outcomes of recipients with HIV by donor HIV testing status.MethodsUsing the Scientific Registry of Transplant Recipients, we identified all primary adult kidney transplant recipients who were HIV‐positive between 1/1/16‐12/31/21. Recipients were grouped into three cohorts according to the donor HIV status based on antibody (Ab) and nucleic acid testing (NAT): Donor Ab−/NAT− (n = 810), Donor Ab+ /NAT− (n = 98), and Donor Ab+/NAT+ (n = 90). We compared recipient and death‐censored graft survival (DCGS) by donor HIV testing status using Kaplan–Meier curves and Cox proportional hazards regression, censored at 3 years posttransplant. Secondary outcomes were delayed graft function (DGF) and the following 1‐year outcomes: acute rejection, re‐hospitalization, and serum creatinine.ResultsIn Kaplan–Meier analyses, patient survival and DCGS were similar by donor HIV status (log rank p = .667; log rank p = .388). DGF occurred more frequently in donors with HIV Ab−/NAT− testing compared with Ab+/NAT− or Ab+/NAT+ testing (38.0% vs. 28.6% vs. 26.7%, p = .028). Average dialysis time before transplant was twice as long for recipients who received organs from donors with Ab−/NAT− testing (p < .001). Acute rejection, re‐hospitalization and serum creatinine at 12 months did not differ between the groups.ConclusionsPatient and allograft survival for recipients living with HIV remains comparable irrespective of donor HIV testing status. Utilizing kidneys from deceased donors with HIV Ab+/NAT− or Ab+/NAT+ testing shortens dialysis time prior to transplant. image
The Role of Pediatric Palliative Care Following Nonaccidental Trauma
Henderson, Trevor G., Graff, Arne H. , Thorvilson, Megan J.

Mayo Clinic

Journal of Palliative Medicine | July 11, 2023 | Volume: 26 | Issue: 12 | Pages: 1752-1754

10.1089/jpm.2023.0165 | PMID 37433212 Get It

All children experiencing child maltreatment/neglect require child abuse experts to offer the complex care needed, and for the child with potential life-limiting injuries, both child abuse and palliative care experts are integral to the team. The current literature describes the involvement of child abuse pediatrics after patients are already engaged with pediatric palliative care (PPC). Here we describe a case of an infant who suffered injuries after nonaccidental trauma (NAT) and the subsequent role of PPC. In the case described, PPC was consulted in the context of a grave neurological prognosis after NAT. The mother retained full decision-making rights, and she wanted to protect her daughter from a life dependent on others and medical technology. Our team supported the mother in the face of multiple layers of loss—her daughter, her relationship with the perpetrator, her home, and the threat of job loss due to time away.
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
Litton, Jennifer K. , Regan, Meredith M. , Pusztai, Lajos , Tolaney, Sara M. , Garrett‐Mayer, Elizabeth , Amiri‐Kordestani, Laleh , Basho, Reva , Boileau, Jean-François , Foster, Jared C. , Jacene, Heather A. , King, Tari A. , Mason, Ginny, O’Sullivan, Ciara C. , Prowell, Tatiana M. , Richardson, Andrea L. , Sepulveda, Karla A., Smith, Mary Lou , Tjoe, Judy A., Turashvili, Gulisa , Butler, Lynn Pearson, Schwartz, Elena I., Korde, Larissa A. , Rugo, Hope S , Tolaney, Sara , Garrett-Mayer, Elizabeth , Amiri-Kordestani, Laleh , Basho, Reva K , Best, Ana F , Boileau, Jean-Francois , Denkert, Carsten , Foster, Jared C , Harbeck, Nadia , Jacene, Heather A , O'Sullivan, Ciara Catherine , Prowell, Tatiana M , Turashvili, Gulisa , Woodward, Wendy A , Pusztai, Lajos , Rugo, Hope S.

Mayo Clinic

Journal of Clinical Oncology | July 11, 2023 | Volume: 41 | Issue: 27 | Pages: 4433-4442

10.1200/jco.23.00435 | PMID 37433103 Get It

PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points. METHODS The NeoSTEEP working group concentrated on neoadjuvant systemic therapy end points in clinical trials with efficacy outcomes—both pathologic and time-to-event survival end points—particularly for registrational intent. Special considerations for subtypes and therapeutic approaches, imaging, nodal staging at surgery, bilateral and multifocal diseases, correlative tissue collection, and US Food and Drug Administration regulatory considerations were contemplated. RESULTS The working group recommends a preferred definition of pathologic complete response (pCR) as the absence of residual invasive cancer in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0 per AJCC staging). Residual cancer burden should be a secondary end point to facilitate future assessment of its utility. Alternative end points are needed for hormone receptor–positive disease. Time-to-event survival end point definitions should pay particular attention to the measurement starting point. Trials should include end points originating at random assignment (event-free survival and overall survival) to capture presurgery progression and deaths as events. Secondary end points adapted from STEEP 2.0, which are defined from starting at curative-intent surgery, may also be appropriate. Specification and standardization of biopsy protocols, imaging, and pathologic nodal evaluation are also crucial. CONCLUSION End points in addition to pCR should be selected on the basis of clinical and biologic aspects of the tumor and the therapeutic agent investigated. Consistent prespecified definitions and interventions are paramount for clinically meaningful trial results and cross-trial comparison.
The Association Between Age at Diagnosis and Disease Characteristics and Damage in Patients With ANCA‐Associated Vasculitis
Bloom, Jessica L. , Pickett‐Nairn, Kaci, Silveira, Lori , Fuhlbrigge, Robert C. , Cuthbertson, David , Akuthota, Praveen , Corbridge, Thomas, Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Rhee, Rennie L. , Silver, Jared , Monach, Paul A , Rhee, Rennie L , Merkel, Peter A , Khalidi, Nader , Monach, Paul A. , Moreland, Larry W. , Pagnoux, Christian , Seo, Philip , Specks, Ulrich , Warrington, Kenneth J. , Wechsler, Michael E , Merkel, Peter A.

Mayo Clinic

Arthritis & Rheumatology | July 11, 2023 | Volume: 75 | Issue: 12 | Pages: 2216-2227

10.1002/art.42651 | PMID 37433067 Get It

ObjectiveThis study examined the relationship between age at diagnosis and disease characteristics and damage in patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).MethodsAnalysis of a prospective longitudinal cohort of patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA) in the Vasculitis Clinical Research Consortium (2013–2021). Disease cohorts were divided by age at diagnosis (years): children (<18), young adults (18–40), middle‐aged adults (41–65), and older adults (>65). Data included demographics, ANCA type, clinical characteristics, Vasculitis Damage Index (VDI) scores, ANCA Vasculitis Index of Damage (AVID) scores, and novel disease‐specific and non‐disease‐specific damage scores built from VDI and AVID items.ResultsAnalysis included data from 1020 patients with GPA/MPA and 357 with EGPA. Female predominance in GPA/MPA decreased with age at diagnosis. AAV in childhood was more often GPA and proteinase 3‐ANCA positive. Children with GPA/MPA experienced more subglottic stenosis and alveolar hemorrhage; children and young adults with EGPA experienced more alveolar hemorrhage, need for intubation, and gastrointestinal involvement. Older adults (GPA/MPA) had more neurologic manifestations. After adjusting for disease duration, medications, tobacco, and ANCA, all damage scores increased with age at diagnosis for GPA/MPA (P < 0.001) except the disease‐specific damage score, which did not differ (P = 0.44). For EGPA, VDI scores increased with age at diagnosis (P < 0.009), whereas all other scores were not significantly different.ConclusionAge at diagnosis is associated with clinical characteristics in AAV. Although VDI and AVID scores increase with age at diagnosis, this is driven by non‐disease‐specific damage items.image
Predictive power of chest radiography for infectious or inflammatory lung disease
Hull, Nate C., Thacker, Paul G. , Boesch, R. Paul , Boesch, Richard P , Hull, Nathan C.

Mayo Clinic

Pediatric Pulmonology | July 11, 2023 | Volume: 58 | Issue: 10 | Pages: 2804-2808

10.1002/ppul.26591 | PMID 37431956 Get It

AbstractObjectiveChildren frequently present with chronic cough, recurrent respiratory infections, and dysphagia. These symptoms are poor predictors of significant inflammatory lung disease, such as from chronic aspiration. Bronchoalveolar lavage (BAL) is the gold standard for identification of lung infection and airway inflammation but is expensive and requires sedation. Chest X‐rays (CXR) are inexpensive, low‐radiation tests that do not require sedations and can document findings associated with infectious or inflammatory lung disease. The accuracy of CXR to predict or exclude infectious or inflammatory lung disease has not been directly evaluated and is unknown.MethodsRetrospective cohort of all pediatric patients who underwent FFB with BAL within 2 weeks of a CXR. Blinded CXR images reviewed for findings consistent with inflammatory disease by two senior pediatric radiologists. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for CXR to identify significant inflammation and/or infection on BAL were calculated.ResultsThree hundred and forty‐four subjects included. Two hundred and sixty‐three had positive CXR (77%), 183 had inflammatory BAL (53%), and 110 had infection (32%). The sensitivity of CXR changes for BAL inflammation, infection, and either inflammation or infection was 84.7, 90.9, and 85.3, respectively. The PPV of CXR was 58.9, 38.0, and 59.7. The NPV of CXR was 65.0, 87.5, and 66.3.ConclusionsAlthough CXR are inexpensive, do not require sedation, and are of low radiation dose, the ability of an entirely normal CXR to exclude active inflammatory or infectious lung disease is limited.
Prognostic value of peripheral endothelial function on major adverse cardiovascular events above traditional risk factors
Rajai, Nazanin , Sara, Jaskanwal Deep Singh , Rajotia, Arush , López-Jiménez, Francisco , Lerman, Lilach O. , Lerman, Amir , Sara, Jaskanwal D, Lopez-Jimenez, Francisco , Lerman, Lilach O , Lerman, Amir , Toya, Takumi

Mayo Clinic

European Journal of Preventive Cardiology | July 11, 2023 | Volume: 30 | Issue: 16 | Pages: 1781-1788

10.1093/eurjpc/zwad225 | PMID 37431927 Get It

Abstract Aims This study aims to identify whether adding peripheral microvascular dysfunction (PMED), a marker of atherosclerosis to established risk scores has an incremental prognostic value for major adverse cardiovascular events (MACE). Methods and results This is a retrospective study of patients who underwent measuring peripheral arterial tonometry from 2006 to 2020. The optimal cut-off value of the reactive hyperaemia index (RHI) that had maximal prognostic value associated with MACE was calculated. Peripheral microvascular endothelial dysfunction was defined as the RHI lower than the cut-off. Traditional cardiovascular risk factors such as age, sex, congestive heart failure, hypertension, diabetes, stroke, and vascular disease were determined to calculate the CHA2DS2-Vasc score. The outcome was MACE defined as myocardial infarction, heart failure hospitalization, cerebrovascular events, and all-cause mortality. A total of 1460 patients were enrolled (average age 51.4 ± 13.6, 64.1% female). The optimal cut-off value of the RHI was 1.83 in the overall population and in females and males was 1.61 and 1.8, respectively. The risk of MACE during 7 [interquartile range (IQR): 5,11] years of follow-up was 11.2%. Kaplan–Meier analysis showed that lower RHI is associated with worse MACE-free survival (P &lt; 0.001). Multivariate Cox proportional hazard analysis, controlling for classic cardiovascular risk factors or risk scores such as CHA2DS2-Vasc and Framingham risk score revealed that PMED is an independent predictor of MACE. Conclusion Peripheral microvascular dysfunction predicts cardiovascular events. Non-invasive assessment of peripheral endothelial function may be useful in early detection and improving the stratification of high-risk patients for cardiovascular events. Lay summary Key findings
FLASH instead of proton arc therapy is a more promising advancement for the next generation proton radiotherapy
Kang, Minglei , Ding, Xuanfeng , Rong, Yi , Rong, Yi

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 11, 2023 | Volume: 24 | Issue: 8 | Pages: No page available

10.1002/acm2.14091 | PMID 37431574 Get It

Osteochondral Allograft Transplantation for the Unstable Capitellar Osteochondritis Dissecans Lesion: An Anconeus Preserving Approach
Feroe, Aliya G. , Langhans, Mark T. , Sanchez-Sotelo, Joaquin, Sánchez‐Sotelo, Joaquín , Morrey, Mark E. , Camp, Christopher L.

Mayo Clinic

Video Journal of Sports Medicine | July 11, 2023 | Volume: 3 | Issue: 4 | Pages: No page available

10.1177/26350254231173701 | PMID 40308668 Get It

Background: Osteochondritis dissecans (OCD) of the capitellum can be a disabling condition that typically affects adolescent, overhead athletes. To date, a variety of different surgical treatment options have been described. Indications: Surgical indications for osteochondral allograft transplantation (OCA) for capitellar OCD lesions include failure of nonsurgical management or prior surgery and unstable, full-thickness lesions of almost any size affecting both bone and cartilage. The anconeus preserving approach specifically provides wide access to nearly the entire capitellum and can be used for lesions in almost any location. Technique Description: The anconeus preserving approach for OCA utilizes the interval between the anconeus and the ulna. With the patient positioned supine and the elbow flexed on an arm table, an incision is made approximately 1 cm lateral to the olecranon and is carried down to the fascia. Electric cautery is used to dissect the interval between the ulna and the anconeus. The anconeus is elevated off the ulna and retracted laterally to expose the underlying joint capsule. An L-shaped capsulotomy is performed over the center of the capitellum, just proximal to the annular ligament of the radial head. A pin is placed into the center of the lesion, perpendicular to the capitellum. A cannulated reamer 0.5 mm smaller than the lesion is used to ream the lesion to a depth of approximately 5 mm. Depth measurements are taken at all 4 poles of the defect. About 3 cc of bone marrow aspirate harvest is then obtained from the ulna using a cannulated needle. The oscillating saw is used to cut the graft to size using the prior measurements. The bone marrow aspirate is placed onto the osseous side of the graft before the osteochondral graft is impacted into the recipient site. The capsulotomy is then closed, and the anconeus is repaired back to the ulna. Postoperatively, patients begin range of motion as soon as tolerated, initiate strengthening at 6 weeks, and initiate return-to-sport programming at 3 months. Results: Lesions treated with OCA typically demonstrate improvement in all outcome measures, including functional scores, graft incorporation, articular surface congruity, and return-to-sport. Complications and graft failure is rare. Discussion/Conclusion: OCA using an anconeus preserving approach is a reliable option for surgical management of unstable OCD lesions. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.